Lithocholic Acid Kills Cancer, Spares Healthy Cells
By LabMedica International staff writers Posted on 19 Jan 2012 |
Lithocholic acid (LCA), naturally generated in the liver during digestion, has been seriously underestimated because new research has revealed that LCA can kill several kinds of cancer cells, such as those found in breast cancer and various brain tumors.
The researchers, led by Concordia University (Austin, TX, USA), included scientists from McGill University (Montreal, Canada) and the Jewish General Hospital’s Lady Davis Institute (Montreal, Canada), as well as the University of Saskatchewan (Saskatoon, Canada). The study’s findings were published October 2011 in the journal Oncotarget.
Earlier research from the same investigators demonstrated LCA also extends the lifespan of aging yeast. This time, the team found LCA to be very selective in killing cancer cells while leaving normal cells unscathed. This could translate into a great improvement over the indiscriminant all-cell damaging drugs used in chemotherapy.
“LCA doesn’t just kill individual cancer cells. It could also prevent the entire tumor from growing,” stated senior author Vladimir Titorenko, a professor in the department of biology and Concordia University research chair in genomics, cell biology, and aging.
Moreover, LCA prevents tumors from releasing substances that cause neighboring cancer cells to grow and proliferate. Prof. Titorenko noted that LCA is the only compound that targets cancer cells, which could translate into tumor-halting power. “This is important for preventing cancer cells from spreading to other parts of the body,” he said, noting that unlike other antiaging compounds, LCA blocks cancer cell growth yet lets normal cells continue to grow.
The next phase for the research team will be to test LCA’s effect on different cancers in mice models. Prof. Titorenko expects that LCA will also kill cancer cells in the research and lead to human clinical trials. “Our study found that LCA kills not only tumors [neuroblastomas], but also human breast cancer cells,” said Prof. Titorenko. “This shows that it has a wide effect on different types of cancers.”
Prof. Titorenko emphasized that dissimilar to agent utilized in chemotherapy, LCA is a natural compound that is already present in humans. Studies have shown that LCA can be safely given to mice by adding it to their food. Therefore, scientists are looking into why LCA is so lethal for cancer cells. Prof. Titorenko conjectures that cancer cells have more sensors for LCA, which makes them more sensitive to the compound than normal cells.
LCA sensors transmit signals to mitochondria. It seems that when these signals are too strong, mitochondria self-destruct and take the cell along with them. Simply stated, Prof. Titorenko and his colleagues engaged in cancer cell disruption by targeting a weakness to LCA.
Related Links:
Concordia University
McGill University
Jewish General Hospital’s Lady Davis Institute
The researchers, led by Concordia University (Austin, TX, USA), included scientists from McGill University (Montreal, Canada) and the Jewish General Hospital’s Lady Davis Institute (Montreal, Canada), as well as the University of Saskatchewan (Saskatoon, Canada). The study’s findings were published October 2011 in the journal Oncotarget.
Earlier research from the same investigators demonstrated LCA also extends the lifespan of aging yeast. This time, the team found LCA to be very selective in killing cancer cells while leaving normal cells unscathed. This could translate into a great improvement over the indiscriminant all-cell damaging drugs used in chemotherapy.
“LCA doesn’t just kill individual cancer cells. It could also prevent the entire tumor from growing,” stated senior author Vladimir Titorenko, a professor in the department of biology and Concordia University research chair in genomics, cell biology, and aging.
Moreover, LCA prevents tumors from releasing substances that cause neighboring cancer cells to grow and proliferate. Prof. Titorenko noted that LCA is the only compound that targets cancer cells, which could translate into tumor-halting power. “This is important for preventing cancer cells from spreading to other parts of the body,” he said, noting that unlike other antiaging compounds, LCA blocks cancer cell growth yet lets normal cells continue to grow.
The next phase for the research team will be to test LCA’s effect on different cancers in mice models. Prof. Titorenko expects that LCA will also kill cancer cells in the research and lead to human clinical trials. “Our study found that LCA kills not only tumors [neuroblastomas], but also human breast cancer cells,” said Prof. Titorenko. “This shows that it has a wide effect on different types of cancers.”
Prof. Titorenko emphasized that dissimilar to agent utilized in chemotherapy, LCA is a natural compound that is already present in humans. Studies have shown that LCA can be safely given to mice by adding it to their food. Therefore, scientists are looking into why LCA is so lethal for cancer cells. Prof. Titorenko conjectures that cancer cells have more sensors for LCA, which makes them more sensitive to the compound than normal cells.
LCA sensors transmit signals to mitochondria. It seems that when these signals are too strong, mitochondria self-destruct and take the cell along with them. Simply stated, Prof. Titorenko and his colleagues engaged in cancer cell disruption by targeting a weakness to LCA.
Related Links:
Concordia University
McGill University
Jewish General Hospital’s Lady Davis Institute
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples